View Financial HealthRedwood Scientific Technologies 배당 및 자사주 매입배당 기준 점검 0/6Redwood Scientific Technologies 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 19Redwood Scientific Technologies Inc. Announces a Strategic Shift in its Product Development PrioritiesRedwood Scientific Technologies Inc. announced a strategic shift in its product development priorities. The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREE and TBX VAPE-FREE. This pivotal decision follows recent findings published by the American College of Cardiology, sourced from a study conducted by the National Institute of Health. The study highlights a significant correlation between e-cigarette use and an increased risk of heart failure, underscoring the urgency for effective and safe alternatives in nicotine replacement therapy. Redwood believes that its TBX-FREE and TBX VAPE-FREE products will be innovative solutions in the realm of nicotine replacement therapy. The company anticipates publication of double blind randomized studies before bringing these products to market. By concentrating its resources on TBX-FREE and TBX VAPE-FREE, Redwood is positioning itself to be at the forefront of a critical market, responding proactively to the latest scientific research and public health needs.공시 • Feb 07Redwood Scientific Technologies Inc. Enters into an Agreement with Jeeva Clinical Trials to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips Products for Smoking and E-CortationRedwood Scientific Technologies Inc. announced that it has entered into an agreement with Jeeva Clinical Trials to launch a clinical effectiveness study of its TBX-Free oral strips products for smoking and e- vaping cessation. The company has engaged top U.S. institution, George Mason University, to conduct the efficacy study on this new product. nicotine - found in cigarettes, vapes and e- vaping - is highly addictive, acting as both a stimulant and a sedative, and has severe adverse effects on every bodily system. It has been reported that 8 million adults in the U.S. regularly use e- vaping, with 28.3 million adults who regularly use traditional cigarettes. Of this number of users, 2.5 million middle and high school students use e- vaping, with 16.5% of high school students report current use of tobacco. The CDC reported that 60% of youth tobacco users have made an attempt to quit. It has also been reported that 54% of e- vaping users have also tried to quit. Unfortunately, nicotine replacement therapies (NRTs) that are currently on the market still rely on the continued use of nicotine. These products include nicotine patches, nasal sprays, gum, and other over the counter, standard-of-care aids that are available. Redwood's TBX-free dissolvable oral strips are nicotine free and rely on the power of cytisine, a more effective active ingredient that is found in golden rain trees (Cytisus Laburnum), mainly in the seeds. Cytisine acts similarly to nicotine where it can stimulate receptors in the brain, nearly identical to e- vaping, allowing the brain to overcome the craving to vape with a lower risk of addiction.공시 • Nov 16Redwood Scientific Technologies Receives Conditional Approval from Irb/Cirb for Groundbreaking Clinical StudiesRedwood Scientific Technologies announced that, as of 11-13-2023 at 10:42 AM, it has secured conditional approval from the Institutional Review Board (IRB)/Central Institutional Review Board (CIRB). This milestone marks a significant advancement in Redwood's ongoing efforts towards clinical study work, aiming to develop and introduce an Oral Thin Film Strip to address nicotine addiction in vape devices. The conditional IRB approval not only paves the way for the study on Redwood's innovative product for nicotine addiction in vape devices but also extends to a study on TBX FREE, the company's primary product designed to combat nicotine addiction in traditional cigarettes. Redwood envisions being the pioneer in the market with a nicotine-free solution for addiction to nicotine in e- vape devices. This conditional approval from IRB/CIRB signifies a crucial step forward for Redwood Scientific Technologies in its commitment to addressing nicotine addiction across various mediums. The company remains dedicated to accelerating the development and market availability of these solutions to make a meaningful impact on the current challenges associated with nicotine dependency.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 RSCI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: RSCI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Redwood Scientific Technologies 배당 수익률 vs 시장RSCI의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (RSCI)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Personal Products)3.2%분석가 예측 (RSCI) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RSCI 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RSCI 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RSCI 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: RSCI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/20 12:16종가2026/05/04 00:00수익2012/03/31연간 수익2011/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Redwood Scientific Technologies, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 19Redwood Scientific Technologies Inc. Announces a Strategic Shift in its Product Development PrioritiesRedwood Scientific Technologies Inc. announced a strategic shift in its product development priorities. The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREE and TBX VAPE-FREE. This pivotal decision follows recent findings published by the American College of Cardiology, sourced from a study conducted by the National Institute of Health. The study highlights a significant correlation between e-cigarette use and an increased risk of heart failure, underscoring the urgency for effective and safe alternatives in nicotine replacement therapy. Redwood believes that its TBX-FREE and TBX VAPE-FREE products will be innovative solutions in the realm of nicotine replacement therapy. The company anticipates publication of double blind randomized studies before bringing these products to market. By concentrating its resources on TBX-FREE and TBX VAPE-FREE, Redwood is positioning itself to be at the forefront of a critical market, responding proactively to the latest scientific research and public health needs.
공시 • Feb 07Redwood Scientific Technologies Inc. Enters into an Agreement with Jeeva Clinical Trials to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips Products for Smoking and E-CortationRedwood Scientific Technologies Inc. announced that it has entered into an agreement with Jeeva Clinical Trials to launch a clinical effectiveness study of its TBX-Free oral strips products for smoking and e- vaping cessation. The company has engaged top U.S. institution, George Mason University, to conduct the efficacy study on this new product. nicotine - found in cigarettes, vapes and e- vaping - is highly addictive, acting as both a stimulant and a sedative, and has severe adverse effects on every bodily system. It has been reported that 8 million adults in the U.S. regularly use e- vaping, with 28.3 million adults who regularly use traditional cigarettes. Of this number of users, 2.5 million middle and high school students use e- vaping, with 16.5% of high school students report current use of tobacco. The CDC reported that 60% of youth tobacco users have made an attempt to quit. It has also been reported that 54% of e- vaping users have also tried to quit. Unfortunately, nicotine replacement therapies (NRTs) that are currently on the market still rely on the continued use of nicotine. These products include nicotine patches, nasal sprays, gum, and other over the counter, standard-of-care aids that are available. Redwood's TBX-free dissolvable oral strips are nicotine free and rely on the power of cytisine, a more effective active ingredient that is found in golden rain trees (Cytisus Laburnum), mainly in the seeds. Cytisine acts similarly to nicotine where it can stimulate receptors in the brain, nearly identical to e- vaping, allowing the brain to overcome the craving to vape with a lower risk of addiction.
공시 • Nov 16Redwood Scientific Technologies Receives Conditional Approval from Irb/Cirb for Groundbreaking Clinical StudiesRedwood Scientific Technologies announced that, as of 11-13-2023 at 10:42 AM, it has secured conditional approval from the Institutional Review Board (IRB)/Central Institutional Review Board (CIRB). This milestone marks a significant advancement in Redwood's ongoing efforts towards clinical study work, aiming to develop and introduce an Oral Thin Film Strip to address nicotine addiction in vape devices. The conditional IRB approval not only paves the way for the study on Redwood's innovative product for nicotine addiction in vape devices but also extends to a study on TBX FREE, the company's primary product designed to combat nicotine addiction in traditional cigarettes. Redwood envisions being the pioneer in the market with a nicotine-free solution for addiction to nicotine in e- vape devices. This conditional approval from IRB/CIRB signifies a crucial step forward for Redwood Scientific Technologies in its commitment to addressing nicotine addiction across various mediums. The company remains dedicated to accelerating the development and market availability of these solutions to make a meaningful impact on the current challenges associated with nicotine dependency.